alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Editorial Note on Part 112
Editorial Note: Nomenclature changes to part 112 appear at 81 FR 49896, July 29, 2016.

§ 112.150 Under this subpart, what requirements apply regarding records? ( a ) You must establish and keep records required under this subpart in accordance with the requirements of subpart O of this part.
( b ) You must establish and keep the following records: ( 1 ) Documentation of your treatment of seeds or beans to reduce microorganisms of public health significance in the seeds or beans, at your farm; or alternatively, documentation (such as a Certificate of Conformance) from your seed supplier that seeds or beans are treated to reduce microorganisms of public health significance and are appropriately handled and packaged following the treatment, in accordance with the requirements of § 112.142(e);
( 2 ) Your written environmental monitoring plan in accordance with the requirements of § 112.145;
( 3 ) Your written sampling plan for each production batch of sprouts in accordance with the requirements of § 112.147(a) and (c);
( 4 ) Documentation of the results of all analytical tests conducted for purposes of compliance with this subpart;
( 5 ) Any analytical methods you use in lieu of the methods that are incorporated by reference in §§ 112.152 and 112.153; and
( 6 ) Documentation of actions you take in accordance with §§ 112.142(b) and (c), 112.146, and 112.148.
##### 



Agreement) Company), Holders).
 Issuance)




---



##### 



2




---



##### 



of of
    
   3




---



##### 



provided, however,
   4




---



##### 



provided (ii)
   5




---



##### 



unless unless
 (provided,
 6




---



##### 



provided, however, ;
 7




---



##### 



provided, however,
 (provided,
 8




---



##### 



provided, however,
  9




---



##### 



provided, however,
 10




---



##### 



11




---



##### 



provided, however,
  provided, however,
 provided, however,
  12




---



##### 



13




---



##### 



provided, however,
   14




---



##### 



15




---



##### 



r




---



##### 



AMERICAN REAL ESTATE PARTNERS, L.P.By: American Property Investors, Inc.,Its general partnerBy:
    
    /s/ Keith MeisterName:
    
    Keith MeisterTitle:
    
    Chief Executive Officer
 HOLDERS:HIGHCREST INVESTORS CORP.,By:
    
    /s/ Richard BuonatoName:
    
    Richard BuonatoTitle:
    
    Senior Vice PresidentARNOS CORP.,By:
    
    /s/ Edward MattnerName:
    
    Edward MattnerTitle:
    
    Vice PresidentCYPRUS, LLCBy: Barberry Corp., Managing MemberBy:
    
    /s/ Edward MattnerName:
    
    Edward MattnerTitle:
    
    Authorized SignatoryGASCON PARTNERSBy:Cigas Corp., Managing General PartnerBy:
    
    /s/ Edward MattnerName:
    
    Edward MattnerTitle:
    
    President
<Page>

                                                                    EXHIBIT 99.1

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of United Stationers Inc. and United
Stationers Supply Co. (collectively, the "Company") on Form 10-K for the year
ended December 31, 2002 as filed with the Securities and Exchange Commission on
the date hereof (the "Report"), I, Richard W. Gochnauer, President and Chief
Executive Officer, of the Company, certify, pursuant to 18 U.S.C. Section 1350,
as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

     (1)  The Report fully complies with the requirements of Section 13(a) or
          15(d) of the Securities Exchange Act of 1934; and

     (2)  The information contained in the Report fairly presents, in all
          material respects, the financial condition and result of operations of
          the Company.

A signed original of this written statement required by Section 906 has been
provided to the Company and will be retained by the Company and furnished to the
Securities and Exchange Commission or its staff upon request.

/s/ Richard W. Gochnauer
----------------------------------------

Richard W. Gochnauer
President and Chief Executive Officer
March 28, 2003
# C_2019195EN.01000201.xml

| 11.6.2019 | EN | Official Journal of the European Union | C 195/2 |
| --- | --- | --- | --- |

11.6.2019

EN

Official Journal of the European Union

C 195/2

---

COUNCIL DECISION

of 6 June 2019

appointing four members of the Management Board of the European Medicines Agency

(2019/C 195/02)

THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (1), and in particular Article 65(1) and (4) thereof,

Whereas:

| (1) | On 30 January 2019, the Commission, acting in accordance with Article 65(1) of Regulation (EC) No 726/2004, presented a list of candidates, representatives of patients’ organisations, doctors’ organisations and veterinarians’ organisations, to be appointed to the Management Board of the European Medicines Agency. The appointment is to be for a three-year term which should start on 15 June 2019. |
| --- | --- |

(1)

On 30 January 2019, the Commission, acting in accordance with Article 65(1) of Regulation (EC) No 726/2004, presented a list of candidates, representatives of patients’ organisations, doctors’ organisations and veterinarians’ organisations, to be appointed to the Management Board of the European Medicines Agency. The appointment is to be for a three-year term which should start on 15 June 2019.

| (2) | The European Parliament considered the list of candidates and submitted its views thereon to the Council on 16 April 2019, |
| --- | --- |

(2)

The European Parliament considered the list of candidates and submitted its views thereon to the Council on 16 April 2019,

HAS ADOPTED THIS DECISION:

Article 1

The following persons are hereby appointed members of the Management Board of the European Medicines Agency for a three-year period starting from 15 June 2019:

| Patients’ organisations | Doctors’ organisations | Veterinarians’ organisations |
| --- | --- | --- |
| Mr Marco GRECO
  Mr Ioannis NATSIS | Mr Wolf-Dieter LUDWIG | Ms Nancy DE BRIYNE |

Patients’ organisations

Doctors’ organisations

Veterinarians’ organisations

Mr Marco GRECO

Mr Ioannis NATSIS

Mr Wolf-Dieter LUDWIG

Ms Nancy DE BRIYNE

Article 2

This Decision shall enter into force on the date of its adoption.

Done at Luxembourg, 6 June 2019.

For the Council

The President

A. BIRCHALL

---

(1)  OJ L 136, 30.4.2004, p. 1.

1

---
[No. 15751-2-III.

Division Three.

November 6, 1997.]

#### The State of Washington, *Respondent,*v. John Alfred Raynor, *Appellant.*

Appeal from a judgment of the Superior Court for Pend Oreille County, No. 95-1-00049-8, Fred L. Stewart, J., entered April 11, 1996. *Affirmed*by unpublished opinion per Sweeney, C.J., concurred in by Schultheis and Brown, JJ.
# L_2019026EN.01000801.xml

| 30.1.2019 | EN | Official Journal of the European Union | L 26/8 |
| --- | --- | --- | --- |

30.1.2019

EN

Official Journal of the European Union

L 26/8

---

COUNCIL DECISION (EU, Euratom) 2019/140

of 28 January 2019

appointing a member, proposed by the Kingdom of the Netherlands, of the European Economic and Social Committee

THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty on the Functioning of the European Union, and in particular Article 302 thereof,

Having regard to the Treaty establishing the European Atomic Energy Community, and in particular Article 106a thereof,

Having regard to the proposal of the Government of the Netherlands,

Having regard to the opinion of the European Commission,

Whereas:

| (1) | On 18 September 2015 and 1 October 2015, the Council adopted Decisions (EU, Euratom) 2015/1600 (1) and (EU, Euratom) 2015/1790 (2) appointing the members of the European Economic and Social Committee for the period from 21 September 2015 to 20 September 2020. |
| --- | --- |

(1)

On 18 September 2015 and 1 October 2015, the Council adopted Decisions (EU, Euratom) 2015/1600 (1) and (EU, Euratom) 2015/1790 (2) appointing the members of the European Economic and Social Committee for the period from 21 September 2015 to 20 September 2020.

| (2) | A member's seat on the European Economic and Social Committee has become vacant following the end of the term of office of Ms Annie VAN WEZEL, |
| --- | --- |

(2)

A member's seat on the European Economic and Social Committee has become vacant following the end of the term of office of Ms Annie VAN WEZEL,

HAS ADOPTED THIS DECISION:

Article 1

Mr A. (Fredy) PELTZER, policy advisor at FNV (Federatie Nederlandse Vakbeweging / The Netherlands Trade Union Confederation), is hereby appointed as a member of the European Economic and Social Committee for the remainder of the current term of office, which runs until 20 September 2020.

Article 2

This Decision shall enter into force on the date of its adoption.

Done at Brussels, 28 January 2019.

For the Council

The President

P. DAEA

---

(1)  Council Decision (EU, Euratom) 2015/1600 of 18 September 2015 appointing the members of the European Economic and Social Committee for the period from 21 September 2015 to 20 September 2020 (OJ L 248, 24.9.2015, p. 53).

1

(2)  Council Decision (EU, Euratom) 2015/1790 of 1 October 2015 appointing the members of the European Economic and Social Committee for the period from 21 September 2015 to 20 September 2020 (OJ L 260, 7.10.2015, p. 23).

2

---
#### § 19.1 Scope.

This part governs the standards of conduct for, and establishes regulations to prevent conflicts of interest by, all Food and Drug Administration employees.
----

----

|   | 1. | I have reviewed the Report; |
|--------|----|-----------------------------|

|   | 2. | based on my knowledge, the Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by the Report; and |
|--------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 3. | based on my knowledge, the financial statements, and other financial information included in the Report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in the Report. |
|--------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----
NO. 06

- 14

- 00195

- CR

IN THE COURT OF APPEALS

SIXTH APPELLATE DISTRICT OF TEXAS

AT TEXARKANA, TEXAS

JERRY LEON MCNEIL

, Appellant

VS.

THE STATE OF TEXAS,

Appellee

TO SAID HONORABLE COURT:

MOTION TO WITHDRAW AS COUNSEL FOR APPELLANT

James P. Fins trom, appointed counsel for Jerry Leon McNeil,

Appellant, moves the Court to allow him to withdraw from

representation of Appellant in this cause and shows the Court that he

tried this case and has examined the record in this cause and is of

the opinion that the appeal is without merit on direct appeal and that

there are no grounds which would arguably support reversal of this

conviction on direct appeal and, further, is of the opinion that

Appellant’s pleas of true to allegations numbered three and four in the

State’s Petition to Revoke Probated Judgment in this cause together ACCEPTED

06-14-00195

SIXTH COURT OF APPEALS

TEXARKANA, TEXAS

1/15/2015 8:47:40 AM

DEBBIE AUTREY

CLERKwith his judicial confession when he entered his plea of guilty in this

cause are wholly sufficient to support the order of the trial court

revoking his probation

.

WHEREFORE, PREMI SES CONSIDERED, counsel for

Appellant moves that he be permitted to withdraw from representation

in this cause

.

Respectfully submitted,

__ /s/ Jame s P. Finstrom

_ James P. Finstrom

Counsel for Appellant

202 S. Marsh all,

P.O. Box 276

Jefferson, Texas 75657

903

- 665

- 7111

Fax: 903

- 665

- 7167

Texas Bar #07038000

CERTIFICATE OF SERVICE

I certify that I have delivered a true copy of this brief to Hon.

Angela Smoak

, counsel for the State

, on t his 15 th day of January,

2015

.

__ /s/ James P. Finstrom

___ James P. Finstrom

2
CERTIFICATION PURSUANT TO SECTION
                          302 OF THE SARBANES OXLEY ACT


I, Jeffrey Ploen, certify that:

1. I have  reviewed  this  quarterly  report  on Form  10-QSB  of Tonga  Capital
Corporation.;

2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;

4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

     a) designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the
period in which this quarterly report is being prepared;

     b) evaluated the effectiveness of the registrant's disclosure controls and
procedures as of March 31, 2005; and

     c) presented in this quarterly report our conclusions about the
effectiveness of the disclosure controls and procedures based on our evaluation
as of the Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent
functions):

     a) all significant deficiencies in the design or operation of internal
controls which could adversely affect the registrant's ability to record,
process, summarize and report financial data and have identified for the
registrant's auditors any material weaknesses in internal controls; and

<PAGE>

     b) any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls; and

6. The registrant's other certifying officers and I have indicated in this
quarterly report whether there were significant changes in internal controls or
in other factors that could significantly affect internal controls subsequent to
the date of our most recent evaluation, including any corrective actions with
regard to significant deficiencies and material weaknesses.

Date:  May 19, 2005


/s/ Jeffrey Ploen
- -----------------------
Jeffrey Ploen, President
Editorial Note on Part 10
Editorial Note: Nomenclature changes to part 10 appear at 68 FR 24879, May 9, 2003, and at 88 FR 45064, July 14, 2023.

§ 10.105 Representation by an organization. ( a ) An organization may represent its members by filing petitions, comments, and objections, and otherwise participating in an administrative proceeding subject to this part.
( b ) A petition, comment, objection, or other representation by an organization will not abridge the right of a member to take individual action of a similar type, in the member's own name.
( c ) It is requested that each organization participating in FDA administrative proceedings file annually with the Dockets Management Staff a current list of all of the members of the organization.
( d ) The filing by an organization of an objection or request for hearing under §§ 12.20 through 12.22 does not provide a member a legal right with respect to the objection or request for hearing that the member may individually exercise. A member of an organization wishing to file an objection or request for hearing must do so individually.
( e ) In a court proceeding in which an organization participates, the Commissioner will take appropriate legal measures to have the case brought or considered as a class action or otherwise as binding upon all members of the organization except those specifically excluded by name. Regardless of whether the case is brought or considered as a class action or as otherwise binding upon all members of the organization except those specifically excluded by name, the Commissioner will take the position in any subsequent suit involving the same issues and a member of the organization that the issues are precluded from further litigation by the member under the doctrines of collateral estoppel or res judicata.
<PAGE>   1

                                                                    Exhibit 23.2


                       CONSENT OF INDEPENDENT AUDITORS



THE BOARD OF DIRECTORS
INNOVA CORPORATION



            We consent to the incorporation by reference in the registration
statement dated August 21, 1997 on Form S-8 of Innova Corporation of our report
dated April 30, 1997, except as to Note 17, which is as of June 17, 1997, 
relating to the consolidated balance sheets of Innova Corporation and 
subsidiary as of March 31, 1996 and December 31, 1996, and the related
consolidated statements of operations, stockholders' deficit, and cash flows 
for each of the years in the two-year period ended March 31, 1996 and for the
nine month fiscal period ended December 31, 1996, and related financial
statement schedule, which reports appear in Innova Corporation's registration
statement (No. 333-29547) on Amendment No. 3 to Form S-1.


                                                   KPMG Peat Marwick LLP


Seattle, Washington
August 21, 1997.
IN THE COURT OF CRIMINAL APPEALS

OF TEXAS

NO. WR-89,429-01

EX PARTE ANTHONY JAMES CASE, Applicant

ON APPLICATION FOR A WRIT OF HABEAS CORPUS

CAUSE NO. 1265680-A IN THE 179 DISTRICT COURT TH

FROM HARRIS COUNTY

Per curiam.

O R D E R

Pursuant to the provisions of Article 11.07 of the Texas Code of Criminal Procedure, the

clerk of the trial court transmitted to this Court this application for a writ of habeas corpus. Ex parte

Young, 418 S.W.2d 824, 826 (Tex. Crim. App. 1967). Applicant was convicted of capital murder

and sentenced to life imprisonment without parole. The Fourteenth Court of Appeals affirmed his

conviction. Case v. State, No. 14-11-00996-CR (Tex. App.—Houston [14 ] Oct. 4, 2012)(not th

designated for publication).

Applicant contends that his trial counsel rendered ineffective assistance by failing to object

to medical records, failing to object to an improper statement by the prosecutor, and admitting to the

jury that he was guilty of murder. 
2

Applicant has alleged facts that, if true, might entitle him to relief. Strickland v. Washington,

466 U.S. 668 (1984); Ex parte Patterson, 993 S.W.2d 114, 115 (Tex. Crim. App. 1999). In these

circumstances, additional facts are needed. As we held in Ex parte Rodriguez, 334 S.W.2d 294, 294

(Tex. Crim. App. 1960), the trial court is the appropriate forum for findings of fact. The trial court

shall order trial counsel to respond to Applicant’s claim of ineffective assistance of counsel. The

trial court may use any means set out in TEX. CODE CRIM. PROC. art. 11.07, § 3(d). 

If the trial court elects to hold a hearing, it shall determine whether Applicant is indigent. 

If Applicant is indigent and wishes to be represented by counsel, the trial court shall appoint an

attorney to represent Applicant at the hearing. TEX. CODE CRIM. PROC. art. 26.04. 

The trial court shall make findings of fact and conclusions of law as to whether the

performance of Applicant’s trial counsel was deficient and, if so, whether counsel’s deficient

performance prejudiced Applicant. The trial court shall also make any other findings of fact and

conclusions of law that it deems relevant and appropriate to the disposition of Applicant’s claim for

habeas corpus relief.

This application will be held in abeyance until the trial court has resolved the fact issues. The

issues shall be resolved within 90 days of this order. A supplemental transcript containing all

affidavits and interrogatories or the transcription of the court reporter’s notes from any hearing or

deposition, along with the trial court’s supplemental findings of fact and conclusions of law, shall

be forwarded to this Court within 120 days of the date of this order. Any extensions of time must

be requested by the trial court and shall be obtained from this Court.

Filed: February 27, 2019

Do not publish
3
**EXHIBIT
      12****Republic
      Bancorp Inc.****Calculations
      of Ratios of Earnings to Combined Fixed Charges****Three
      Months Ended**(in
      thousands)
    
    **March****2005**
    
    
    **2004****Including
      Interest on Deposits:**Fixed
      charges:Total
      interest expense
    
    $
    37,513
    
    
    $
    31,940Interest
      portion of rent expense
    
    
    200
    
    
    
    194Fixed
      charges including interest on deposits
    
    $
    37,713
    
    
    $
    32,134Earnings:Net
      income
    
    $
    17,307
    
    
    $
    16,299Income
      taxes
    
    
    7,687
    
    
    
    6,872Fixed
      charges, as above
    
    
    37,713
    
    
    
    32,134Earnings
      for purposes of calculation
    
    $
    62,707
    
    
    $
    55,305Ratio
      of earnings to combined fixed charges includinginterest
      on deposits
    
    
    1.66
    x
    
    
    1.72
    
    x**Excluding
      Interest on Deposits:**Fixed
      charges:Total
      interest expense excluding interest on deposits
    
    $
    22,325
    
    
    $
    18,903Interest
      portion of rent expense
    
    
    200
    
    
    
    194Fixed
      charges excluding interest on deposits
    
    $
    22,525
    
    
    $
    19,097Earnings:Net
      income
    
    $
    17,307
    
    
    $
    16,299Income
      taxes
    
    
    7,687
    
    
    
    6,872Fixed
      charges, as above
    
    
    22,525
    
    
    
    19,097Earnings
      for purposes of calculation
    
    $
    47,519
    
    
    $
    42,268Ratio
      of earnings to combined fixed charges excludinginterest
      on deposits
    
    
    2.11
    x
    
    
    2.21
    
    x
###### Editorial Note on Part 312

#### Editorial Note:

Nomenclature changes to part 312 appear at 69 FR 13717, Mar. 24, 2004.

#### § 312.83 Treatment protocols.

If the preliminary analysis of phase 2 test results appears promising, FDA may ask the sponsor to submit a treatment protocol to be reviewed under the procedures and criteria listed in §§ 312.305 and 312.320. Such a treatment protocol, if requested and granted, would normally remain in effect while the complete data necessary for a marketing application are being assembled by the sponsor and reviewed by FDA (unless grounds exist for clinical hold of ongoing protocols, as provided in § 312.42(b)(3)(ii)).

[53 FR 41523, Oct. 21, 1988, as amended at 76 FR 13880, Mar. 15, 2011]